Under construction – not a live service
Sign in
Taking people in BelgiumNo phase

Accelerated Magnetic Stimulation for Depression That Did Not Respond to ECT

Tests repeated magnetic brain stimulation in adults with depression who responded poorly to ECT.

Plain-language title generated from the registry record
Registry title: Accelerated TMS for Treatment-Resistant ECT

Key facts

Where
Jette, BelgiumSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Source: NCT07115628, who can take part

Where in Belgium

  • UZ BrusselJette, BelgiumTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Universitair Ziekenhuis Brussel
Trial code
NCT07115628
Record updated
11 August 2025
Original description
This study investigates whether an additional treatment using transcranial magnetic stimulation (TMS) can help severely depressed patients who did not respond well to electroconvulsive therapy (ECT).Read full original descriptionShow less

Accelerated dTMS Treatment for ECT-non Responders

This study investigates whether an additional treatment using transcranial magnetic stimulation (TMS) can help severely depressed patients who did not respond well to electroconvulsive therapy (ECT).

All participants will first receive standard ECT treatment for depression, including brain scans (fMRI), psychological testing, clinical assessments, and the collection of blood and stool samples. If the ECT treatment is not effective, patients will be invited to participate in a second part of the study where they receive a 4-day course of accelerated TMS (20 sessions in total).

The study aims to assess whether this additional TMS treatment can reduce depressive symptoms. The study also explores how brain structure, genetics, and gut health may relate to treatment success. In total, 200 patients will be included.

Inclusion: Diagnosis of Major Depressive Disorder (MDD); Age between 18 - 70 years; Referred for ECT treatment.

Exclusion: A personal history of seizures or epilepsy, a history of seizures or epilepsy in first degree relatives and the presence of any known factor that can lower the seizure threshold (sleep deprivation, abuse substance, etc.), previous head injury and the presence of metallic implants in the cephalic region (e.g., aneurysm clips, shunts, stimulators, cochlear implants, electrodes) except dental fill-ings and the presence of cardiac pacemakers, neurostimulators, surgical clips or other electronic equipment, comorbidity with some neurological disorders: increased intracranial pressure, space-occupying lesion, history of stroke or transient ischemic attack, brain aneurysm and any structural brain damage with increased risk for epilepsy detected with MRI; Suicide attempt within 6 months before the start of the study or pre-sent risk of suicide per the investigator's clinical judgment; Patients with cognitive disturbances or dementia (Mini Mental State) < 24.

ClinicalTrials.gov NCT07115628